News

• August 31, 2023

  Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference >

  BALA CYNWYD, Pa. , Aug. 31, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc.   (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in a panel discussion and 1x1

• August 10, 2023

  Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results >

  Initiation cleared for 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial following FDA review of unblinded 25 mg cohort Phase 2 data Initiation cleared for open-label extension (OLE) trial following FDA review of unblinded 25 mg cohort Phase 2 data Top-line safety,

• July 25, 2023

  Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial >

  Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024 Initiation of open label extension trial with 25 mg daily dosing expected in Q1 2024; interim data expected in Q4 2024 Company management hosting a webcast and

• July 17, 2023

  Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer >

  BALA CYNWYD, Pa. , July 17, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Russell “Rusty” Clayton, DO, as Chief Medical Officer

• June 21, 2023

  Larimar Therapeutics Set to Join Russell 3000® Index >

  BALA CYNWYD, Pa. , June 21, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it is set to join the broad-market Russell 3000 Index at the conclusion

• May 15, 2023

  Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’s Ataxia and First Quarter 2023 Financial Results >

  Safety data indicate that repeated subcutaneous injections of 25 mg CTI-1601 were generally well tolerated when administered daily for 14 days and then every-other-day thereafter until day 28 Daily subcutaneous injections of 25 mg CTI-1601 for 14 days led to increases in frataxin levels from

• March 28, 2023

  Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days >

  BALA CYNWYD, Pa. , March 28, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in a virtual fireside chat and 1x1

• March 14, 2023

  Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results >

  First cohort of Larimar’s Phase 2 dose exploration trial of CTI-1601 in participants with Friedreich’s ataxia (FA) is fully enrolled and proceeding as planned Larimar expects to provide an update on the next steps of the Phase 2 trial in Q2 2023, after the FDA and independent data monitoring

• February 7, 2023

  Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer >

  Biologics expert and long-time veteran of Johnson & Johnson will be responsible for the strategic development of Larimar’s clinical and R&D programs BALA CYNWYD, Pa. , Feb. 07, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company

• November 21, 2022

  Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference >

  BALA CYNWYD, Pa. , Nov. 21, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will present and participate in 1x1 investor

• November 10, 2022

  Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results >

  First cohort of Larimar’s Phase 2 dose exploration trial of CTI-1601 in Friedreich’s ataxia patients is ongoing and proceeding in line with the Company’s planned timeline Larimar expects to provide an update on the Phase 2 trial in Q2 2023 and anticipates reporting top-line data from both cohorts

• November 7, 2022

  Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day >

  BALA CYNWYD, Pa. , Nov. 07, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in a virtual fireside chat and 1x1

• October 20, 2022

  Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601 >

  Patent extends Larimar’s intellectual property protection for CTI-1601 into at least July 2040 BALA CYNWYD, Pa. , Oct. 20, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare

• October 19, 2022

  Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research >

  BALA CYNWYD, Pa. , Oct. 19, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company’s Phase 1 clinical program evaluating CTI-1601 as

• September 16, 2022

  Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares >

  BALA CYNWYD, Pa. , Sept. 16, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previously announced underwritten

• September 14, 2022

  Larimar Therapeutics Announces $70 Million Underwritten Offering >

  BALA CYNWYD, Pa. , Sept. 14, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of an underwritten offering of 22,225,000

• September 14, 2022

  Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients >

  Initiation of the Phase 2 trial is expected in Q4 2022, with top-line data expected in 2H 2023 Company management hosting webcast and conference call today at 8:30 a.m. ET BALA CYNWYD, Pa. , Sept. 14, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage

• August 11, 2022

  Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results >

  Larimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022 In conjunction with the complete response, Larimar is proposing a Phase 2, four-week dose exploration study in Friedreich’s ataxia (FA)   patients as CTI-1601’s next clinical trial Cash and

• July 28, 2022

  Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders >

  BALA CYNWYD, Pa. , July 28, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that preclinical studies evaluating CTI-1601’s effects on gene expression

• June 28, 2022

  Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts >

  BALA CYNWYD, Pa. , June 28, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that biomarker studies that have identified genes that are differentially

• June 2, 2022

  Larimar Therapeutics Announces Upcoming Scientific Conference Presentations >

  BALA CYNWYD, Pa. , June 02, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced upcoming presentations at the United Mitochondrial Disease Foundation

• May 19, 2022

  Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress >

  BALA CYNWYD, Pa. , May 19, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company’s Phase 1 clinical program evaluating CTI-1601 as

• May 12, 2022

  Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results >

  - CTI-1601 Type C Meeting to discuss clinical hold has been granted by the U.S. Food and Drug Administration and is scheduled for early in the third quarter of 2022 - Cash at March 31, 2022 of $62.6 million provides projected cash runway into the third quarter of 2023 BALA CYNWYD, Pa.

• March 25, 2022

  Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results >

  BALA CYNWYD, Pa. , March 25, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its full year 2021 operating and financial results.

• February 14, 2022

  Larimar Therapeutics Provides Update on CTI-1601 Clinical Program >

  BALA CYNWYD, Pa. , Feb. 14, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has received feedback from the U.S.

---

View all News >